BioVie is set to report topline data from its Phase 3 trial in Alzheimer's disease, with a high likelihood of reaching statistical significance. Blinded data from the trial showed a reduction in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback